Insulet 향후 성장

Future 기준 점검 4/6

Insulet (는) 각각 연간 23.9% 및 14.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 23.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.5% 로 예상됩니다.

핵심 정보

23.9%

이익 성장률

23.68%

EPS 성장률

Medical Equipment 이익 성장	12.7%
매출 성장률	14.7%
향후 자기자본이익률	18.45%
애널리스트 커버리지	Good
마지막 업데이트	03 Oct 2025

최근 향후 성장 업데이트

Recent updates

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

Sep 06

There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Aug 14

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

Aug 14

Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26%

May 15

We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease

Apr 21

Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?

Apr 07

Insulet Leans Bullish (Technical Analysis)

Mar 18

Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Mar 05

Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital

Feb 18

Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)

Jan 25

What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?

Jan 13

Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly

Dec 18

Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors

Dec 04

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Nov 20

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Nov 20

Returns At Insulet (NASDAQ:PODD) Are On The Way Up

Nov 08

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Oct 15

Insulet: Turning More Constructive, Valuations Still Stretched

Sep 05

Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks

Aug 22 Expansion into new international markets and integration with leading diabetes sensors position Insulet for increased global penetration and competitive advantage.

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Jun 11

Insulet: Insulating Patients, Investors Still Have To Wait

Mar 28

이익 및 매출 성장 예측

NasdaqGS:PODD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	3,643	509	525	681	19
12/31/2026	3,105	407	471	586	23
12/31/2025	2,625	264	375	467	23
6/30/2025	2,360	236	392	516	N/A
3/31/2025	2,199	402	281	407	N/A
12/31/2024	2,072	418	296	430	N/A
9/30/2024	1,984	421	209	318	N/A
6/30/2024	1,873	395	173	276	N/A
3/31/2024	1,781	234	137	233	N/A
12/31/2023	1,697	206	37	146	N/A
9/30/2023	1,557	120	-15	151	N/A
6/30/2023	1,465	63	-26	152	N/A
3/31/2023	1,368	1	-45	133	N/A
12/31/2022	1,305	5	-38	119	N/A
9/30/2022	1,243	17	-63	43	N/A
6/30/2022	1,178	35	-141	-40	N/A
3/31/2022	1,142	45	-152	-47	N/A
12/31/2021	1,099	17	-191	-68	N/A
9/30/2021	1,037	-29	-199	-26	N/A
6/30/2021	996	-30	-126	44	N/A
3/31/2021	959	9	-120	53	N/A
12/31/2020	904	7	-82	84	N/A
9/30/2020	868	29	-15	114	N/A
6/30/2020	826	18	-25	101	N/A
3/31/2020	777	5	-65	88	N/A
12/31/2019	738	12	-72	98	N/A
9/30/2019	694	17	-74	82	N/A
6/30/2019	653	17	-103	67	N/A
3/31/2019	600	14	N/A	47	N/A
12/31/2018	564	3	N/A	36	N/A
9/30/2018	529	-13	N/A	27	N/A
6/30/2018	500	-17	N/A	35	N/A
3/31/2018	486	-23	N/A	59	N/A
12/31/2017	464	-27	N/A	41	N/A
9/30/2017	437	-29	N/A	39	N/A
6/30/2017	410	-30	N/A	19	N/A
3/31/2017	387	-26	N/A	5	N/A
12/31/2016	367	-27	N/A	16	N/A
9/30/2016	347	-34	N/A	-23	N/A
6/30/2016	324	-49	N/A	-17	N/A
3/31/2016	297	-62	N/A	-20	N/A
12/31/2015	264	-62	N/A	-13	N/A
9/30/2015	253	-51	N/A	11	N/A
6/30/2015	256	-44	N/A	7	N/A
3/31/2015	268	-56	N/A	6	N/A
12/31/2014	231	-48	N/A	9	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PODD 의 연간 예상 수익 증가율(23.9%)이 saving rate(3.1%)보다 높습니다.

수익 vs 시장: PODD 의 연간 수익(23.9%)이 US 시장(15.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: PODD 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: PODD 의 수익(연간 14.7%)이 US 시장(연간 9.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: PODD 의 수익(연간 14.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PODD의 자본 수익률은 3년 후 18.5%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/05 20:23
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Insulet Corporation는 63명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Anand Vankawala	Avondale Partners
null null	Baird
Jeffrey Johnson	Baird

Insulet 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Insulet Corporation Updates Revenue Guidance for the Full Year Ending December 31, 2025

Insulet Corporation Provides Revenue Guidance for the Full Year Ending December 31, 2025

Price target increased by 7.0% to US$313

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2025 and Full Year Ending December 31, 2025

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Recent updates

Now 21% overvalued after recent price rise

Insulet Corporation Announces Chief Financial Officer Changes, Effective September 30, 2025

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher

Insulet Corporation Announces Executive Appointments

Executive VP notifies of intention to sell stock

There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Insulet Corporation Updates Revenue Guidance for the Full Year Ending December 31, 2025

Insulet (NASDAQ:PODD) Has A Rock Solid Balance Sheet

Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?

Insulet Corporation to Report Q2, 2025 Results on Aug 07, 2025

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users

What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?

Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Insulet Corporation Provides Revenue Guidance for the Full Year Ending December 31, 2025

Insulet Corporation, Annual General Meeting, May 22, 2025

Insulet Corporation Announces Management Changes, Effective April 28, 2025

We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease

Insulet Corporation Launches Omnipod 5 Automated Insulin Delivery System in Canada

Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?

Insulet Corporation to Report Q1, 2025 Results on May 08, 2025

Insulet Corporation Announces Executive Changes

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery (Aid) System Now Available in Australia

Insulet Leans Bullish (Technical Analysis)

Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Price target increased by 7.0% to US$313

Full year 2024 earnings: EPS exceeds analyst expectations

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2025 and Full Year Ending December 31, 2025

Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital

Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)

Executive VP notifies of intention to sell stock

Now 21% overvalued after recent price rise

Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe

What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?

Insulet Corporation to Report Q4, 2024 Results on Feb 20, 2025

Executive VP recently sold US$1.2m worth of stock

Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly

Executive VP notifies of intention to sell stock

Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Returns At Insulet (NASDAQ:PODD) Are On The Way Up

Omnipod 5 App for Iphone Now Fully Available in the United States

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold US$1.1m worth of stock

Independent Chairman notifies of intention to sell stock

Insulet: Turning More Constructive, Valuations Still Stretched

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 9.0% overvalued after recent price rise

Now 20% overvalued after recent price rise

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold US$1.3m worth of stock

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Independent Chairman notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024